KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Free Cash Flow (2018 - 2025)

Historic Free Cash Flow for Moderna (MRNA) over the last 8 years, with Q3 2025 value amounting to -$880.0 million.

  • Moderna's Free Cash Flow rose 4874.78% to -$880.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.7 billion, marking a year-over-year increase of 3293.73%. This contributed to the annual value of -$4.1 billion for FY2024, which is 601.31% down from last year.
  • Per Moderna's latest filing, its Free Cash Flow stood at -$880.0 million for Q3 2025, which was up 4874.78% from -$922.0 million recorded in Q2 2025.
  • Moderna's 5-year Free Cash Flow high stood at $4.0 billion for Q2 2021, and its period low was -$1.7 billion during Q3 2023.
  • Moreover, its 5-year median value for Free Cash Flow was $163.0 million (2022), whereas its average is $372.7 million.
  • In the last 5 years, Moderna's Free Cash Flow soared by 970238.1% in 2021 and then plummeted by 116748.47% in 2023.
  • Quarter analysis of 5 years shows Moderna's Free Cash Flow stood at $3.2 billion in 2021, then plummeted by 50.78% to $1.6 billion in 2022, then tumbled by 74.39% to $402.0 million in 2023, then dropped by 24.63% to $303.0 million in 2024, then plummeted by 390.43% to -$880.0 million in 2025.
  • Its Free Cash Flow stands at -$880.0 million for Q3 2025, versus -$922.0 million for Q2 2025 and -$1.2 billion for Q1 2025.